SCDT-44. CLINICAL EVALUATION OF REGADENOSON AS A PHARMACOLOGIC AGENT TO TRANSIENTLY MODIFY BLOOD-BRAIN BARRIER INTEGRITY TO FACILITATE ENTRY OF CHEMOTHERAPY INTO BRAIN PARENCHYMA

Previous pre-clinical and rodent studies have demonstrated that adenosine A2A receptor activation can transiently modify: 1) blood-brain barrier (BBB) integrity thereby increasing entry of high molecular weight dextran and temozolomide to the central nervous system, 2) the actions of p-glycoprotein...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Grossman, Stuart, Rudek, Michelle, Jackson, Sadhana, Bynoe, Margaret
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2017
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691893/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.1124
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky